Proto-Oncogene Proteins B-raf

A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.

Also Known As:

B-raf Kinases; BRAF Kinases; Proto-Oncogene Protein B-raf; B raf Kinase; B raf Kinases; B-raf, Proto-Oncogene Protein; B-raf, Proto-Oncogene Proteins; Kinase, B-raf; Kinase, BRAF; Protein B-raf, Proto-Oncogene; Proteins B-raf, Proto-Oncogene; Proto Oncogene Protein B raf; Proto Oncogene Proteins B raf; B-raf Kinase; BRAF Kinase

Networked: 281 relevant articles (20 outcomes, 28 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Garbe, Claus: 6 articles (01/2018 - 06/2011)
2.	Dummer, Reinhard: 5 articles (01/2018 - 06/2011)
3.	Ribas, Antoni: 5 articles (01/2016 - 09/2010)
4.	Long, Georgina V: 5 articles (09/2015 - 09/2013)
5.	Kim, Kevin B: 5 articles (05/2014 - 09/2010)
6.	Aiba, Setsuya: 4 articles (09/2021 - 01/2019)
7.	Fujimura, Taku: 4 articles (09/2021 - 01/2019)
8.	Kambayashi, Yumi: 4 articles (09/2021 - 01/2019)
9.	Ascierto, Paolo A: 4 articles (01/2020 - 04/2014)
10.	Flaherty, Keith T: 4 articles (01/2019 - 09/2010)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 07/01/2012 - "Aberrant activation of the BRAF kinase occurs in ∼60% of melanomas, and although BRAF inhibitors have shown significant early clinical success, acquired resistance occurs in most patients. " 11/01/2017 - "The development of BRAF kinase inhibitors as targeted treatments for patients with BRAF-mutant tumours contributed profoundly to an improved overall survival of patients with metastatic melanoma. " 02/01/2012 - "Much effort has been put into the use of different target-specific drugs, among which BRAF kinase-specific small-molecule inhibitors have rendered promising results as therapeutic agents in metastatic melanoma. " 10/01/2019 - "BRAF kinase inhibitors have shown promise in the treatment of late-stage melanoma; however, there have been no studies and only one previous case report regarding its use in pregnancy. " 01/01/2019 - "BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials."
2.	Neoplasms (Cancer) 09/27/2023 - "Collectively, our study provides valuable insights into the activation mechanism of BRAF kinase and may help to guide the development of new therapeutic strategies for cancer treatment." 06/22/2022 - "Various BRAF kinase inhibitors were developed to treat cancers carrying the BRAFV600E mutation. " 11/15/2020 - "B-Raf kinase plays a significant role in healthy cell growth in the MAPK pathway and the problem associated with B-Raf mutation leads to the development of cancer and other diseases. " 01/01/2020 - "BRAF kinase, a critical effector of the ERK signaling pathway, is hyperactivated in many cancers. " 01/01/2020 - "The V600E mutation in the BRAF gene has been detected in various tumors, resulting in a 500-fold increase in BRAF kinase activity. "
3.	Thyroid Neoplasms (Thyroid Cancer) 11/01/2023 - "Our study provides mechanistic insights into how thyroid cancer poorly responds to B-Raf kinase inhibitors and suggests that targeting B-Raf and the Shh pathway in combination may overcome thyroid cancer drug resistance." 09/01/2023 - "Thus, this study not only determines the potential antitumor activity of Pin1 inhibitor API-1 in thyroid cancer but also offers an alternative therapeutic strategy for BRAF-mutant thyroid cancers by a combination of Pin1 inhibitor and BRAF kinase inhibitor." 10/01/2016 - "The aim of our study was to inhibit BRAF kinase expression and investigate its effect on cellular functions in thyroid carcinomas. " 02/08/2023 - "However, its antitumor activity in thyroid cancer and its effect on cellular response to BRAF kinase inhibitors remain unclear. " 01/01/2019 - "Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions. "
4.	Colonic Neoplasms (Colon Cancer) 11/01/2012 - "In the present study, we examined whether inhibition of the Raf-1 or b-Raf kinase decreases cell growth and increases apoptosis in colon cancer cells. " 01/01/2017 - "Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer." 12/01/2020 - "These observations imply that the therapeutic efficacy of MEK kinase inhibitors or BRAF kinase inhibitors against KRAS-mutated colon cancer cells may differ between MSI-H and MSS. " 12/01/2020 - "Based on these collective data, we propose that MSI status should be considered when MEK kinase inhibitor or BRAF kinase inhibitor is treated for KRAS-mutated colon cancer, and that combination of both inhibitors synergistically inhibit proliferation of KRAS-mutated colon cancer cells independent of MSI status." 12/01/2020 - "Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability."
5.	Brain Neoplasms (Brain Tumor) 06/01/2017 - "Brain tumors harbor various BRAF alterations, the vast majority of which are the BRAF kinase-activating V600E mutation. " 10/01/2013 - "Low-grade brain tumors (pilocytic astrocytomas) that result from a genomic rearrangement in which the BRAF kinase domain is fused to the amino terminal of the KIAA1549 gene (KIAA1549:BRAF fusion; f-BRAF) commonly arise in the cerebellum of young children. " 01/01/2014 - "Dabrafenib, a reversible inhibitor of mutant BRAF kinase, improved response rates and median progression-free survival in patients with V600E BRAF-mutant metastatic melanoma, including those with brain metastases. " 02/01/2014 - "We investigated the BRAF kinase inhibitor vemurafenib in patients with advanced melanoma with symptomatic brain metastases. " 11/01/2019 - "Dual inhibitor therapy using dabrafenib (a selective oral inhibitor of several mutated forms of BRAF kinase) and trametinib (a reversible inhibitor of MEK1 and MEK2) has been used successfully for treatment of metastatic melanoma, anaplastic thyroid cancer, and other tumor types, but has been reported in only a few patients with primary brain tumors and none with pleomorphic xanthoastrocytoma. "

Related Drugs and Biologics

1.	Vemurafenib
2.	dabrafenib
3.	Mitogen-Activated Protein Kinase Kinases (MEKs)
4.	Dacarbazine (DIC)
5.	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)
6.	trametinib
7.	Ipilimumab
8.	Immune Checkpoint Inhibitors
9.	Proteins (Proteins, Gene)
10.	Mitogen-Activated Protein Kinases

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Drug Therapy (Chemotherapy)
4.	Precision Medicine
5.	Biological Therapy